Iron Deficiency Anemia in Patients with Chronic Kidney Disease
Treatment of iron deficiency anemia in patients with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis.        
In patients with CKD on hemodialysis, IV iron superior to orally administered iron in increasing hemoglobin concentrations and/or minimizing dosage of an erythropoiesis-stimulating agent (ESA); the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guidelines state that the IV route of iron administration is preferred in such patients.
Available data suggest that iron sucrose and sodium ferric gluconate may be associated less frequently with serious adverse effects (e.g., hypersensitivity reactions) than iron dextran.   
Iron sucrose injection also used as iron maintenance therapy in children with dialysis-dependent (hemodialysis or peritoneal dialysis) or non-dialysis-dependent CKD. (See Pediatric Use under Cautions.)
